Professor Sebastian Stintzing addresses the clinical question ‘What is the relevance of molecular subtypes in GI tumors?’
Professor Sebastian Stintzing addresses the clinical question ‘What is the relevance of molecular subtypes in GI tumors?’
Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin. His research focuses on the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany. Prof. Stintzing is member of national and international cancer associations, member of the German S3 Guideline committee for colorectal cancer, and member of the steering committee of the working group Colorectal Carcinoma of the German AIO.
AMGEN, AstraZeneca, Bayer, BMS, CV6, Eisai, Isofol, Lilly, Merck KGaA, MSD, Pierre Fabre, Roche, Sanofi, Taiho, Takeda
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast
How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?
Understanding the role of molecular subtypes in guiding treatment selection
Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.